FDA Approves SKYRIZI for Pediatric Psoriatic Disease, Expanding Market for AbbVie
ABBV sits 38% above its 52-week low of $181.73 on elevated volume (7.5× avg).
Summary
AbbVie's blockbuster drug SKYRIZI has received FDA approval for pediatric use in patients aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This approval includes a new 55 mg pre-filled syringe for weight-based dosing, making SKYRIZI the first and only IL-23 inhibitor approved for this specific pediatric population. The expanded indication opens a new patient demographic, reinforcing the drug's market position and contributing to AbbVie's immunology portfolio growth. This positive regulatory news follows recent strong financial results and the strategic acquisition of Apogee Therapeutics.
At the time of this announcement, ABBV was trading at $251.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $447.6B. The 52-week trading range was $181.73 to $253.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.